Journey Medical Co. (NASDAQ:DERM) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its position in Journey Medical Co. (NASDAQ:DERM) by 13.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 108,435 shares of the company’s stock after acquiring an additional 12,882 shares during the period. Geode Capital Management LLC’s holdings in Journey Medical were worth $613,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Nwam LLC bought a new position in Journey Medical during the third quarter worth $59,000. Kovitz Investment Group Partners LLC acquired a new stake in shares of Journey Medical during the third quarter worth $66,000. TMD Wealth Management LLC acquired a new stake in shares of Journey Medical during the second quarter worth $65,000. ORG Wealth Partners LLC bought a new position in shares of Journey Medical in the 3rd quarter worth about $110,000. Finally, PVG Asset Management Corp acquired a new position in shares of Journey Medical in the 2nd quarter valued at about $894,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Price Performance

DERM opened at $3.83 on Friday. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The company’s 50-day moving average price is $4.96 and its 200 day moving average price is $5.23. Journey Medical Co. has a fifty-two week low of $2.85 and a fifty-two week high of $6.89. The firm has a market cap of $80.01 million, a price-to-earnings ratio of -4.07 and a beta of 1.00.

Journey Medical Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.